By Dr. Jeremy Bleicher, DO, MPH | May 2026
One of the more consistent concerns I hear from patients before they start a GLP-1 agent is a version of this: I don’t want to lose muscle. They’ve read something, or a friend told them, or they found a forum post, and now they’re worried that the weight coming off won’t be the right kind of weight. The concern is legitimate and worth taking seriously rather than dismissing. But the answer is more nuanced than most of what circulates online, and getting it right matters both for how patients approach treatment and for how clinicians support them through it.
Any calorie-deficit intervention produces some loss of lean mass alongside fat loss. This is not unique to GLP-1 receptor agonists. It is a basic physiological response to negative energy balance. The body draws on multiple fuel sources during weight loss, and skeletal muscle protein is among them, particularly when caloric restriction is steep, protein intake is insufficient, or physical activity declines during the process. The question is not whether some lean mass loss occurs but whether it is clinically meaningful, how it compares to other weight loss approaches, and what can be done about it.
What the Body Composition Data Actually Shows
The clinical trial programs for semaglutide and tirzepatide both captured body composition data using DXA scanning in subgroups, giving us a reasonably clear picture of how weight loss breaks down between fat mass and lean mass in patients treated with GLP-1 agents.
In the STEP 1 trial for semaglutide, the average participant losing approximately 15 percent of body weight showed roughly 70 to 75 percent of that loss coming from fat mass and 25 to 30 percent from lean mass. The lean mass loss was proportional to the total weight loss rather than disproportionate to it. In other words, the ratio of fat to lean in the weight coming off was broadly consistent with what you see in well-managed caloric restriction programs.
Tirzepatide’s body composition data from SURMOUNT showed a similar pattern, with fat mass comprising the majority of weight lost. At the highest doses, where average weight loss approaches 20 percent of body weight, some analyses suggest the fat-to-lean ratio may be slightly more favorable than with semaglutide, though the comparison is complicated by different trial designs and participant characteristics. The headline result across both agents is that the weight being lost is predominantly fat, and the lean mass loss is proportional rather than excessive.
What the trials do not show, and this is the part worth stating clearly, is that GLP-1 agents uniquely spare muscle in a way that defies normal physiology. The lean mass loss is real. It is not a crisis in the typical patient, but it is not zero, and for patients who are starting with lower muscle reserves, for older adults in particular, it warrants attention.
Why Older Patients Face a Different Calculation
Sarcopenia, the age-related loss of skeletal muscle mass and function, is already a clinical concern in adults over 60 independent of weight management. Muscle mass declines naturally at roughly 1 percent per year after middle age, with a steeper decline after 70. In patients who already have reduced muscle reserves, adding a weight loss intervention that carries lean mass loss as a component, even a proportional one, requires more careful management than it does in a younger, well-muscled patient losing 20 pounds.
I’ve seen this play out clinically. A 68-year-old patient of mine started tirzepatide and lost 18 percent of her body weight over 14 months, which was a terrific metabolic outcome by every measure that mattered: blood pressure normalized, her HbA1c came down from 7.4 to 5.9, and she came off two medications. She also reported feeling weaker going up stairs, which she hadn’t before. DXA confirmed she had lost about 4 kilograms of lean mass alongside 18 kilograms of fat. For a younger patient, that lean mass loss would be easy to address with exercise. For her, at 68, it required deliberate intervention.
This is not an argument against treating obesity in older adults. Obesity in older adults carries its own functional consequences, and the cardiometabolic improvements that accompany GLP-1 treatment are highly relevant at that age. It is an argument for monitoring lean mass proactively and having a specific plan for preserving it when the patient’s starting point makes it a concern.
The Role of Protein Intake
Dietary protein is the primary nutritional lever for limiting lean mass loss during caloric deficit. The mechanism is straightforward: adequate protein intake provides the amino acid substrate for muscle protein synthesis and reduces the degree to which the body draws on muscle protein to meet metabolic needs during negative energy balance. The general recommendation for patients on GLP-1 agents pursuing active weight loss is to prioritize protein intake at every meal, targeting somewhere in the range of 1.2 to 1.6 grams of protein per kilogram of body weight daily, which is meaningfully higher than standard dietary guidelines and considerably higher than what most patients currently eat.
The practical challenge is that GLP-1 receptor agonism reduces appetite substantially. A patient who previously ate 2,200 calories a day may find themselves genuinely satisfied at 1,400 calories while on a therapeutic dose. Getting adequate protein into a significantly reduced caloric intake requires intentional food selection and, for many patients, protein supplementation. Whey protein, casein, and other complete protein sources work well and are easy to fit into a reduced-calorie day.
In practice, I ask patients to think about protein first at every meal. If the stomach is smaller in capacity because of slowed gastric emptying, use that capacity on the food that protects muscle. Vegetables and dietary fat can come after protein is accounted for. The patients who come back with the best body composition outcomes at one year are almost uniformly the ones who internalized this early in treatment.
Resistance Training Is Not Optional
Exercise is the other side of the equation, and within the exercise category, resistance training is the component that specifically preserves lean mass during weight loss. Aerobic exercise is valuable for cardiovascular fitness and overall energy expenditure, but it does not provide the mechanical stimulus that signals skeletal muscle to maintain itself during caloric restriction. Resistance training does. The signal is load-bearing mechanical stress on muscle fibers, which upregulates muscle protein synthesis and partially counteracts the catabolic effect of negative energy balance.
The practical dose is two to three sessions per week of compound resistance movements, meaning exercises that engage large muscle groups through a full range of motion. Squats, deadlifts, rows, presses, and their machine-based equivalents all work. The goal is not to become a competitive lifter. It is to provide enough mechanical stimulus that skeletal muscle has a reason to maintain itself while the body is otherwise losing weight.
Patients on GLP-1 agents who exercise consistently preserve lean mass significantly better than sedentary patients losing the same amount of weight. This is not a hypothesis. The body composition data supports it, and it is consistent with what basic exercise physiology would predict. When I have patients who are concerned about muscle loss, the first thing I tell them is that the medication does not control this outcome as much as their behavior does.
Understanding how each GLP-1 medication handles appetite suppression and caloric reduction differently helps patients plan their nutrition and exercise strategy accordingly, since the magnitude of appetite suppression varies enough between agents that it affects how aggressively protein and exercise need to be prioritized.
Monitoring Body Composition in Practice
Routine scale weight is a poor proxy for body composition changes. A patient can be losing fat and gaining muscle simultaneously and show minimal scale movement, which they may interpret as the medication not working. Conversely, rapid scale weight loss early in treatment often includes a significant water component from glycogen mobilization and reduced sodium retention, which has nothing to do with fat or muscle and reverses as the body equilibrates.
DXA scanning is the gold standard for body composition measurement and is available at most academic medical centers and many outpatient clinics. It provides separate measures of fat mass, lean mass, and bone mineral density from a low-dose X-ray exposure. For patients where body composition is a clinical concern, especially older adults and those with significant obesity-related sarcopenia, a baseline DXA at treatment initiation gives a reference point against which to measure six and twelve month changes.
For practices without ready DXA access, bioelectrical impedance analysis using a validated device offers a reasonable alternative. The accuracy is lower and the results vary with hydration status, but the directional trend over time is useful. What I avoid is relying on scale weight and BMI alone in patients where lean mass is a clinical priority. Those numbers tell you how heavy someone is. They tell you nothing about what the weight is made of.
The Muscle Mass Question in Context
Patients worry about losing muscle on GLP-1 agents, and the worry is worth taking seriously. What it does not warrant is refusing effective obesity treatment out of concern for a side effect that is manageable with appropriate nutrition and exercise. The alternative, leaving significant obesity untreated, carries its own consequences for muscle function, including through the mechanical stress that excess weight places on joints, the inflammatory effects of visceral adiposity on muscle tissue, and the physical limitations that reduce activity and accelerate muscle loss over time.
The patients who do best on long-term GLP-1 treatment are the ones who treat it as a metabolic intervention to be supported with behavior, not a passive process that happens to them while they wait. Adequate protein intake and consistent resistance training are not optional additions to GLP-1 treatment for patients who care about body composition. They are what separates a good outcome from a great one. My job is to make sure patients understand that before they start, so they can build the habits early while the appetite suppression is motivating rather than adapting to the medication and deciding the habits can wait.
___
Dr. Jeremy Bleicher, DO, MPH, is an endocrinologist specializing in diabetes, thyroid disease, and metabolic syndrome, and a contributing medical writer at WeightLossPills.com.
0 Comments